drugset / Trial / NCT02556918
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
RandomizedParallel-groupSingle-blindPrevention
Summary
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is effective in maintaining blood sugar control in patients with type 2 diabetes (T2D).
Timeline
- Start
- 2016-01
- Primary completion
- 2018-11-06
- Completion
- 2018-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitagliptin | Small molecule | 50 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |
| Background | Insulin Lispro | Protein / enzyme biologic | — | — |
| Background | Regular Human Insulin | Protein / enzyme biologic | — | Intravenous |
| Background | insulin aspart | Protein / enzyme biologic | — | — |
| Background | insulin glargine | Protein / enzyme biologic | — | — |